Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Genetics Expects to Raise $12M in Public Offering of Stock

NEW YORK (GenomeWeb) – Cancer Genetics has priced a public offering of 3 million shares of its common stock at $4 per share, the company said today.

The firm is also offering five-year warrants to purchase 3 million shares of common stock at an exercise price of $5 per share. Cancer Genetics has granted the underwriters a 45-day option to purchase up to 450,000 additional shares of common stock and/or warrants.

In a document filed with the US Securities and Exchange Commission today, the Rutherford, New Jersey-based molecular diagnostics firm said it expects gross proceeds of $12 million and net proceeds of $10.5 million after expenses from the offering.

Joseph Gunnar & Co. and Feltl and Company are joint book runners for the offering while Axiom Capital Management is co-manager.

The offering is expected to close on or around Nov. 12.

Shares of Cancer Genetics were down 15 percent this morning on the Nasdaq at $3.90.

Last month, Cancer Genetics bought the assets of Response Genetics — which had filed for Chapter 11 bankruptcy — for $14 million.

The Scan

Foxtail Millet Pangenome, Graph-Based Reference Genome

Researchers in Nature Genetics described their generation of a foxtail millet pangenome, which they say can help in crop trait improvement.

Protein Length Distribution Consistent Across Species

An analysis in Genome Biology compares the lengths of proteins across more than 2,300 species, finding similar length distributions.

Novel Genetic Loci Linked to Insulin Resistance in New Study

A team reports in Nature Genetics that it used glucose challenge test data to home in on candidate genes involved in GLUT4 expression or trafficking.

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.